11.99
Kura Oncology Inc stock is traded at $11.99, with a volume of 3.81M.
It is up +8.61% in the last 24 hours and up +37.19% over the past month.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
See More
Previous Close:
$11.04
Open:
$11.22
24h Volume:
3.81M
Relative Volume:
2.16
Market Cap:
$1.06B
Revenue:
$71.64M
Net Income/Loss:
$-294.57M
P/E Ratio:
-3.5812
EPS:
-3.348
Net Cash Flow:
$-84.46M
1W Performance:
+9.30%
1M Performance:
+37.19%
6M Performance:
+20.26%
1Y Performance:
+111.09%
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
KURA
Kura Oncology Inc
|
11.99 | 1.06B | 71.64M | -294.57M | -84.46M | -3.348 |
|
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
919.94 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
190.46 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story? - Yahoo Finance
Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones - AD HOC NEWS
Kura Oncology offers stock options to five new hires - Stock Titan
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Kura Oncology reports $5.8 million revenue in Q1 2026 - scanx.trade
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2000 Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA) - TradingView
Kura Oncology, Inc. Actuals & Estimates (HAM:KUR) - TradingView
Kura Oncology, Inc. liabilities 2021-2025 - Statista
Kura Oncology, Inc. Actuals & Estimates (DUS:KUR) - TradingView
KURA Forecast — Price Target — Prediction for 2027 - TradingView
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Insiders At Kura Oncology Sold US$1.5m In Stock, Alluding To Potential Weakness - 富途牛牛
Kura Oncology CMO Mollie Leoni sells $834,283 in common stock By Investing.com - Investing.com Australia
Form 4 Kura Oncology Inc For: 22 June By Investing.com - Investing.com Nigeria
Kura Oncology CMO Mollie Leoni sells $834,283 in common stock - Investing.com
Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan - Stock Titan
Understanding the Setup: (KURA) and Scalable Risk - Stock Traders Daily
[144] Kura Oncology, Inc. SEC Filing - Stock Titan
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kura Oncology Inc (KURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kura Oncology Inc (KURA) Institutional Confidence - TradingKey
Kura Oncology Inc (KURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kura Oncology Inc (KURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kura Oncology Inc (KURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KURA Reiterates by Citizens -- Price Target Maintained at $24.00 - GuruFocus
Citizens reiterates Kura Oncology stock rating on strong trial data By Investing.com - Investing.com South Africa
Citizens reiterates Kura Oncology stock rating on strong trial data - Investing.com
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA) - The Globe and Mail
Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
KURA: Ziftomenib plus 7+3 shows high response and survival rates in AML, supporting phase III trials - TradingView
KURA: Ziftomenib plus 7+3 shows high, durable remission and survival in AML, supporting phase III trials - TradingView
KURA: Ziftomenib demonstrates high remission rates and strong safety in AML, supporting global expansion - TradingView
Kura Oncology Inc EHA Investor Event Transcript - GuruFocus
Number of shareholders of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML - marketscreener.com
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term - GlobeNewswire
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
The Technical Signals Behind (KURA) That Institutions Follow - Stock Traders Daily
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):